Robert D. Aiken

Robert D. Aiken

Neurology

11 Overlook Road
MAC II, Suite 180 Null
Summit, NJ 07901

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Phase 2 trial of personal dendritic cell vaccines in newly diagnosed glioblastoma: 3-year follow-up and correlations with survival.

Phase 2 trial of personal dendritic cell vaccines in newly diagnosed glioblastoma: 3-year follow-up and correlations with survival.

Journal: Human vaccines & immunotherapeutics

Published: September 12, 2025

Author Correction: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial.

Author Correction: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial.

Journal: Nature medicine

Published: July 21, 2025

Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial.

Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial.

Journal: JAMA oncology

Published: November 17, 2022

Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment.

Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment.

Journal: Journal of experimental & clinical cancer research : CR

Published: September 29, 2022

Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial.

Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial.

Journal: Nature medicine

Published: August 20, 2022

Leptomeningeal disease in glioblastoma: endgame or opportunity?

Leptomeningeal disease in glioblastoma: endgame or opportunity?

Journal: Journal of neuro-oncology

Published: August 11, 2021

Generation of glioblastoma patient-derived organoids and mouse brain orthotopic xenografts for drug screening.

Generation of glioblastoma patient-derived organoids and mouse brain orthotopic xenografts for drug screening.

Journal: STAR protocols

Published: March 05, 2021

Oncolytic virus in gliomas: a review of human clinical investigations.

Oncolytic virus in gliomas: a review of human clinical investigations.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: January 06, 2021

BRAINSTORM: A Multi-Institutional Phase 1/2 Study of RRx-001 in Combination With Whole Brain Radiation Therapy for Patients With Brain Metastases.

BRAINSTORM: A Multi-Institutional Phase 1/2 Study of RRx-001 in Combination With Whole Brain Radiation Therapy for Patients With Brain Metastases.

Journal: International journal of radiation oncology, biology, physics

Published: August 22, 2019

A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma.

A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 21, 2019

Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration.

Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration.

Journal: Journal for immunotherapy of cancer

Published: December 20, 2018

Correction to: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.

Correction to: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.

Journal: Journal of translational medicine

Published: June 08, 2018

Showing 1-12 of 19

Last Updated: 09/26/2026